Second anticancer CAR T therapy receives FDA approval

Nature Reviews Drug Discovery 16, 818 (2017). doi:10.1038/nrd.2017.249 Author: Asher Mullard The FDA's approval of Gilead Sciences and Kite Pharmaceutical's axicabtagene ciloleucel for relapsed or refractory large B cell lymphoma in October marked the second green light for the emerging chimeric antigen receptor (CAR) T cell modality. In August, the agency approved Novartis's tisagenlecleucel
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: News and Analysis Source Type: research